Nowadays, finding a drug target – which is a particular molecule specific to a disease which can be actioned upon – is harder than ever.
Fancy Making A Drug? You May Want To Create A Diagnostic First.
Ochre Bio co-founder and CEO, Jack O’Meara, spoke to Medtech Insight about the company’s human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how a fledgling drug company's early work can mirror that seen in diagnostics.
